Literature DB >> 3758108

Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers.

P A van Zwieten.   

Abstract

The heterogeneity of the several subgroups of calcium-antagonistic drugs requires a rigid and well-defined differentiation of this type of agents. From the chemical point of view verapamil-like drugs, dihydropyridines, benzothiazepines and diphenylalkylamines should be distinguished. Among these largely different groups no obvious relationship between chemical structure and calcium-antagonistic activity can be recognized. Irrespective of the chemical classification all above-mentioned compounds inhibit the entry of calcium into cells. However, from a pharmacological point of view a distinction should be made between calcium channel blockers and calcium overload blockers. Calcium channel blockers selectively and competitively inhibit the transmembranous slow inward current, which is carried by calcium ions both in cardiac tissues and in vascular smooth muscle under physiological conditions. However, calcium overload blockers only inhibit the overload of the cell with calcium ions, which occurs under pathological, ischemic conditions. Finally, a survey is given of the various subtypes of calcium-antagonistic drugs with respect to their organ specificity and therapeutic applicability.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758108     DOI: 10.1159/000116061

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

Review 1.  Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension.

Authors:  P Sever
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

2.  Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action.

Authors:  A Oros; M J Houtman; P Neco; A M Gomez; S Rajamani; P Oosterhoff; N J Attevelt; J D Beekman; M A G van der Heyden; L Ver Donck; L Belardinelli; S Richard; G Antoons; M A Vos
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 3.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

4.  L-type voltage-dependent calcium channels do not modulate aminergic neurotransmitter release induced by transient global cerebral ischaemia: an in vivo microdialysis study in rat.

Authors:  D Bentué-Ferrer; R Decombe; B Saïag; H Allain; J Van den Driessche
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

Review 5.  Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.

Authors:  R Massingham; P A Van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.